ChariotMS, the world’s first clinical trial to test whether Mavenclad (cladribine) can slow the worsening of upper limb function in people with progressive multiple sclerosis (MS), has now enrolled 100 participants. The announcement means the Phase 2 trial (NCT04695080) has reached 50% of its target recruitment goal.
Women with multiple sclerosis (MS) have significantly lower relapse rates after entering menopause, but disability levels increase significantly in that period, according to a pooled analysis of studies. The findings are consistent with a decrease in immune activity with age and loss of estrogen, leading to fewer disease-related relapses,…
Two non-pharmacological rehabilitation approaches — one using a computer program designed to improve working memory and the other involving standardized cognitive-behavioral group sessions — both improved the cognitive function of people with progressive forms of multiple sclerosis (MS), a new study reported. While varying medications often are used as…
People with multiple sclerosis (MS) who receive vaccines against influenza — commonly known as flu shots — as well as diphtheria, polio, pneumoccocus, and multiple other pathogens are not significantly more likely to be hospitalized due to a disease relapse, according to a new study in France. Similar…
Octave Bioscience plans to test its precision care program in an observational, real-world study with people with multiple sclerosis (MS). The program, called MS Precision Care Solution, uses blood biomarkers to monitor disease activity alongside MRI scans of the brain and spinal cord. An app tracks…
Innodem Neurosciences has signed a multi-year agreement with Novartis Canada to continue developing Innodem’s digital biomarker eye-tracking technology, a noninvasive method to monitor disease progression in multiple sclerosis (MS). The multimillion-dollar commercial agreement comes on the heels of promising data from an observational trial, sponsored by…
Levels of GFAP protein in the blood — a marker of damage to support cells in the brain — were associated with the enlargement of brain lesions and of fluid-filled brain cavities called ventricles in people with relapsing-remitting MS (RRMS) undergoing Tysabri (natalizumab) treatment, a study showed. While…
Pilates exercise with a relaxation technique improved walking abilities and self-awareness among people with multiple sclerosis (MS), according to a small study. The study, “Impact of Pilates suspension with self-awareness on gait and metacognition in multiple sclerosis: Randomized, single-blinded and parallel-group trial,” was published in…
People with multiple sclerosis (MS) with a rapid decline in walking abilities were more likely to be older when first examined, female, or Black, according to a large data study in the U.S. Other factors associated with worsening walking impairment over time included living with MS longer, having progressive…
Neurologists in the U.S. are largely satisfied with current treatment options for relapsing-remitting multiple sclerosis (RRMS), but opportunities remain for therapies in development, according to a new report by Spherix Global Insights. In the report series, called RealTime Dynamix: Multiple Sclerosis (U.S.), an ongoing survey of healthcare…
Vitamin D reduced the signs of inflammation and nerve damage in a rat model of progressive multiple sclerosis (MS), a study shows. Low levels of the vitamin have been extensively linked with a higher risk of developing relapsing forms of the disease, but studies of vitamin D supplementation in…
Neurofilament light chain (NfL) protein levels can be used to assess neurodegeneration in children and adolescents with neurological disease, including multiple sclerosis (MS), even when they are not experiencing any symptoms, a study has found. The protein already had been established as a biomarker of disease activity and poor…
Treatment with Tecfidera (dimethyl fumarate) provides a similar long-term benefit for Black and Hispanic people with multiple sclerosis (MS) as is found in other racial and ethnic populations, according to five years of data from the real-world ESTEEM study. The study — which assessed the long-term safety and…
NX210c, an investigational therapy for multiple sclerosis (MS) and other neurodegenerative diseases from Axoltis Pharma, will have its clinical development boosted as part of a collaboration with InSilicoTrials. The companies will use InSilicoTrials’ simulation platform to replicate the brain and spinal cord characteristics of people with neurological disorders…
People with multiple sclerosis (MS) living in the U.K. who identified as South Asian reported their first symptoms at a significantly younger age than self-reported white and Black individuals, according to preliminary data from the ADAMS project. ADAMS, which stands for the genetic Association study of individuals from…
Elevated blood levels of neurofilament light chain (NfL), a marker of nerve damage, are associated with long-term disability progression in people with multiple sclerosis (MS) — even among those without acute relapses or MRI disease activity — a study revealed. The results demonstrate the potential utility of NfL blood…
Mavenclad (cladribine) is equally as effective as Gilenya (fingolimod) in reducing relapse rates among multiple sclerosis (MS) patients with highly active disease, according to a new real-world comparison. Disability worsening and the development of new lesions also were similar between the two patient groups — but…
Outcomes are better for people with relapsing-remitting multiple sclerosis (RRMS) initially treated with higher efficacy disease-modifying therapies (DMTs) than for those who begin with lower efficacy DMTs and escalate to more effective treatments as the disease progresses, according to a real-world analysis of patient registry data. Findings also…
Aubagio (teriflunomide), an approved therapy for relapsing forms of multiple sclerosis (MS), works by shifting the balance between activated subsets of nerve-damaging immune cells to those with immunosuppressive traits, a new study reveals. Further studies to understand how changes in immune cell subsets drive Aubagio’s clinical effectiveness will…
Researchers identified a genetic variant that associated with faster multiple sclerosis (MS) progression and greater brain tissue damage, according to a study that combined data on more than 12,500 patients in North America, Europe and Australia. Unlike previously detected MS-related variants linked to the immune system, this variant sits…
The government of Canada soon will provide new income benefits designed to help Canadians living with a disability — including people with multiple sclerosis (MS). Applauded by MS Canada, a nonprofit that actively advocated for these benefits, the announcement follows the passing of the Canada Disability Benefit Act,…
Nearly 80% of adults with highly active relapsing-remitting multiple sclerosis (RRMS) were free of relapses or confirmed disability worsening two years after receiving stem cell transplant, according to a real-world study in Denmark. Moreover, more than two-thirds (69%) of these RRMS patients achieved a clinical outcome called NEDA-3, or…
Among four antibody-based therapies for multiple sclerosis (MS), Ocrevus (ocrelizumab) works best to prevent disability progression and other measures of disease activity in people with PPMS, or primary progressive MS, a review study found. However, the medication is associated with an increased risk of infection, data suggested.
GlobeStar Therapeutics (GSTC) is teaming up with Advanced Innovative Partners (AIP) to design and implement clinical trials of Project Amethyst, an investigational therapy for multiple sclerosis (MS) that aims to reduce neurodegeneration — when nerve cells in the body lose function and ultimately die. The new memorandum of understanding (MOU)…
Changes in the gene activity within immune T-cells explain why women with multiple sclerosis (MS) improve during pregnancy, a study reports. Gene activity changes during and after pregnancy were highly similar between MS patients and healthy women. Many of the genes whose activity was altered during pregnancy were associated…
Altered blood levels of certain fat molecules implicated in inflammatory responses seem to correlate with disability status and markers of nerve damage in people with multiple sclerosis (MS), particularly in those with progressive forms of the disorder, a study reported. Findings highlight the potential role of these fat, or…
The over-the-counter antihistamine clemastine has demonstrated an ability to repair myelin, the protective coating on nerve fibers that’s damaged in multiple sclerosis (MS), according to an analysis of MRI data from the ReBUILD clinical trial. The changes in myelin were examined with a noninvasive MRI method that more…
A blood-clotting protein called fibrin can activate immune cells in the brain and contribute to inflammation and neurodegeneration in multiple sclerosis (MS), a study revealed. Because blood vessels become leaky in neurodegenerative conditions like MS, the blood can cross into the brain, which is known to activate multiple pro-inflammatory…
A detailed examination of nerve tissue isolated from multiple sclerosis (MS) patients showed changes to the myelin sheath before the appearance of substantial inflammatory activity and lesions, a study reported. In MS patients, normal-appearing brain regions showed a less compact, detached, and disorganized myelin composition that may make…
A non-invasive treatment called acute intermittent hypoxia, or AIH, involving periods of oxygen deprivation, was found to ease signs and symptoms of progressive multiple sclerosis (MS) in a mouse model of the disease. Given during the peak of disease activity, AIH treatment — basically, periods of reduced oxygen exposure…
Get regular updates to your inbox.
